ImaginAb, Singapore Radiopharmaceuticals sign Master Service Agreement

Wednesday, August 8, 2012 10:31 AM

ImaginAb, an Inglewood, Calif.-based developer of in vivo molecular imaging agents, has signed a Master Service Agreement (MSA) with Singapore Radiopharmaceuticals, a subsidiary of Fortis HealthCare.

"This agreement represents an important component of our expansion program in Singapore as we establish R&D and pre-clinical imaging capabilities there," said Christian Behrenbruch, Ph.D., CEO of ImaginAb. "Singapore Radiopharmaceuticals has an excellent track record in custom radiochemistry and cGMP product manufacturing and we are pleased to transition our ad hoc collaboration to a more robust alliance."

ImaginAb's technology enables antibodies to be re-engineered into smaller proteins (fragments) with fast kinetics suitable for diagnostic imaging, while maintaining target biospecificity. In this way, true companion in vivo diagnostics can be rapidly developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner. ImaginAb has over a dozen development programs with global biopharma companies to develop companion diagnostic imaging agents to therapeutic antibody drugs (in phase I to BLA), as well as an internal pipeline targeting unmet clinical needs, such as the staging of metastatic prostate and pancreatic cancer.

"ImaginAb has an exciting product pipeline and an extensive pharma client base in need of cGMP radiochemistry services for clinical trials in all corners of the world," said Dr. Nevil Chimon, CEO of Singapore Radiopharmaceuticals. "ImaginAb's presence in Singapore is a visible part of Singapore's growing footprint in molecular imaging and nuclear medicine."

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs